KCM
FLXN

Kingdon Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Kingdon Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-893,580
Closed -$7.35M – 87
2021
Q2 		$7.35M Sell
893,580
-175,000
-16% -$1.49M 0.85% 41
2021
Q1 		$9.56M Hold
1,068,580
– – 0.98% 36
2020
Q4 		$12.3M Hold
1,068,580
– – 1.33% 22
2020
Q3 		$11.1M Sell
1,068,580
-101,315
-9% -$1.24M 1.25% 25
2020
Q2 		$15.4M Buy
1,169,895
+280,317
+32% +$2.91M 1.4% 20
2020
Q1 		$7M Sell
889,578
-94,346
-10% -$1.42M 1.28% 29
2019
Q4 		$20.4M Hold
983,924
– – 3.07% 11
2019
Q3 		$13.5M Buy
983,924
+55,000
+6% +$653K 1.59% 27
2019
Q2 		$11.4M Buy
928,924
+44,906
+5% +$518K 1.12% 29
2019
Q1 		$11M Buy
884,018
+300,000
+51% +$4.01M 1.48% 28
2018
Q4 		$6.61M Buy
584,018
+9,535
+2% +$149K 1% 39
2018
Q3 		$10.7M Sell
574,483
-514,737
-47% -$11.8M 0.75% 51
2018
Q2 		$28.2M Buy
1,089,220
+203,000
+23% +$5.27M 1.96% 10
2018
Q1 		$19.9M Hold
886,220
– – 1.57% 17
2017
Q4 		$22.2M Buy
886,220
+2,899
+0.3% +$71K 1.43% 20
2017
Q3 		$21.4M Sell
883,321
-70,548
-7% -$1.66M 1.39% 18
2017
Q2 		$19.3M Sell
953,869
-137,182
-13% -$2.86M 1.32% 26
2017
Q1 		$29.4M Sell
1,091,051
-288,435
-21% -$5.89M 1.61% 16
2016
Q4 		$26.2M Buy
1,379,486
+311,865
+29% +$5.96M 1.27% 26
2016
Q3 		$20.9M Sell
1,067,621
-29,842
-3% -$505K 0.96% 26
2016
Q2 		$16.4M Buy
1,097,463
+437,000
+66% +$5.49M 0.9% 32
2016
Q1 		$6.08M Sell
660,463
-109,440
-14% -$1.33M 0.33% 68
2015
Q4 		$14.8M Sell
769,903
-65,822
-8% -$1.14M 0.72% 47
2015
Q3 		$12.4M Sell
835,725
-232,415
-22% -$5.45M 0.6% 49
2015
Q2 		$23.4M Buy
1,068,140
+36,500
+4% +$736K 0.91% 35
2015
Q1 		$23.2M Sell
1,031,640
-5,849
-0.6% -$135K 0.99% 22
2014
Q4 		$20.9M Buy
1,037,489
+464,132
+81% +$8.41M 0.91% 34
2014
Q3 		$10.5M Buy
573,357
+58,891
+11% +$853K 0.47% 60
2014
Q2 		$6.91M Buy
514,466
+113,566
+28% +$1.55M 0.27% 102
2014
Q1 		$6.59M Buy
+400,900
New +$6.93M 0.34% 86

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingdon Capital Management's FLXN Position: Q3 2021 in Review

Kingdon Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2021, closing a stake of 893,580 shares — an estimated $7.35M sold.

Kingdon Capital Management first reported a position in FLXN in Q1 2014 and held it in 30 quarters. The position peaked at $29.4M in Q1 2017. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

  • Kingdon Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Kingdon Capital Management sold 893,580 Flexion Therapeutics, Inc. shares in Q3 2021, an estimated $7.35M.
  • Kingdon Capital Management first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 30 quarters.
  • Kingdon Capital Management's Flexion Therapeutics, Inc. position peaked at $29.4M in Q1 2017.
  • 145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Kingdon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.